Skip to main content
Log in

Evaluation of the Surveillance of Hemolytic Uremic Syndrome in British Columbia

Should It Remain Reportable?

  • Published:
Canadian Journal of Public Health Aims and scope Submit manuscript

Abstract

Background

Hemolytic Uremic Syndrome (HUS) was made reportable in British Columbia (BC) in 1998 to detect, control and prevent verotoxigenic Escherichia coli (VTEC) cases. Concerns about under-reporting of HUS cases triggered the assessment of the sensitivity and timeliness of the reporting process in order to guide recommendations around reportability of this syndrome in BC.

Methods

The BC hospitalization database was used to estimate the total number of HUS cases from April 30, 1998 to December 31, 2005. HUS and VTEC cases reported in the integrated Public Health Information System (iPHIS), and HUS cases reported by a surveillance form were linked to hospitalized cases. The proportion of HUS cases detected by each of the surveillance processes was assessed. The time interval between onset of diarrhea and reporting of HUS and VTEC cases to the BC Centre for Disease Control was compared.

Results

57 HUS cases were hospitalized. Sensitivity of reporting through the surveillance form and through iPHIS was 7.0% and 19.3%, respectively. The median time interval between onset of diarrhea and reporting of both HUS and VTEC cases to iPHIS was seven days. The median time interval for reporting HUS cases via the surveillance form was 25 days.

Conclusions

HUS cases were severely under-reported, the timeliness of reporting of these cases had no advantage when compared to the reporting of VTEC cases, and no public health action aimed at reducing the transmission of VTEC infections resulted from this surveillance system. The reportability of HUS in BC needs to be reconsidered, or its surveillance considerably improved.

Résumé

Contexte

Afin de détecter, de traiter et de prévenir les cas d’infection à E. coli producteur de vérotoxine (ECPV), la Colombie-Britannique a rendu obligatoire la déclaration du syndrome hémolytique urémique (SHU) en 1998. Par crainte que les cas de SHU soient sous-déclarés, il a été décidé d’évaluer la sensibilité et l’opportunité du processus de notification en vue de formuler des recommandations sur la déclaration du syndrome dans la province.

Méthode

D’après la base de données des hospitalisations de la C.-B., nous avons estimé le nombre total de cas de SHU survenus entre le 30 avril 1998 et le 31 décembre 2005. Les cas de SHU et d’ECPV déclarés dans le système intégré d’information sur la santé publique (SIISP) et les cas de SHU déclarés sur des fiches de surveillance ont été reliés aux cas hospitalisés. Nous avons calculé la proportion des cas de SHU détectés par chacun des processus de surveillance. Nous avons ensuite comparé l’intervalle entre l’apparition d’une diarrhée et la déclaration des cas de SHU et d’ECPV au BC Centre for Disease Control.

Résultats

Cinquante-sept cas de SHU ont été hospitalisés. La sensibilité des déclarations sur les fiches de surveillance et dans le SIISP était de 7 % et de 19,3 %, respectivement. L’intervalle médian entre l’apparition de la diarrhée et la déclaration des cas de SHU et d’ECPV au SIISP était de sept jours. L’intervalle médian de déclaration des cas de SHU sur les fiches de surveillance était de 25 jours.

Conclusion

Les cas de SHU étaient fortement sous-déclarés, la déclaration des cas de SHU était beaucoup moins rapide que pour les cas d’ECPV, |et le système de surveillance du SHU n’a entraîné aucune mesure de santé publique visant à réduire la transmission des infections à ECPV. Il faudrait soit revoir la pertinence de déclarer les cas de SHU en C.-B., soit améliorer considérablement le système de surveillance du syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Proulx F, Sockett P. Prospective surveillance of Canadian children with the haemolytic uraemic syndrome. Pediatr Nephrol 2005;29:786–90.

    Article  Google Scholar 

  2. Cummings KC, Mohle-Boetani JC, Werner SB, Vugia DJ. Population-based trends in pediatric hemolytic uremic syndrome in California, 1994–1999: Substantial underreporting and public health implications. Am J Epidemiol 2002;155(10):941–48.

    Article  PubMed  Google Scholar 

  3. Chang HGH, Tserenpuntsag B, Kacica M, Smith PF, Morse DL. Hemolytic uremic syndrome incidence in New York. Emerg Infect Dis 2004;10(5):928–31.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tserenpuntsag B, Chang HG, Smith PF, Morse DL. Hemolytic uremic syndrome risk and Escherichia coli O157:H7. Emerg Infect Dis 2005;11(12):1955–57.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073–86.

    CAS  PubMed  Google Scholar 

  6. McCarthy TA, Barett NL, Hadler JL, Salsbury B, Howard RT, Dingman DW, et al. Hemolytic-Uremic Syndrome and Escherichia coli O121 at a lake in Connecticut, 1999. Pediatrics 2001;108:59–66.

    Article  Google Scholar 

  7. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression. JAMA 2003;290(10):1379–81.

    Article  Google Scholar 

  8. Amirlak I, Amirlak B. Haemolytic uraemic syndrome: An overview. Nephrology 2006;11:213–18.

    Article  PubMed  Google Scholar 

  9. Heyman DL. Control of Communicable Diseases Manual, 18th edition. Washington, DC: American Public Health Association, 2003;160–64.

    Google Scholar 

  10. British Columbia Annual Summary of Reportable Diseases: Annual Report 2005. Vancouver, BC: British Columbia Centre for Disease Control, 2005.

    Google Scholar 

  11. Centers for Disease Control and Prevention. Updated guidelines for evaluating public health surveillance systems: Recommendations from the guidelines working group. MMWR 2001;50(13):1–25.

    Google Scholar 

  12. Begue RE, Mehta DI, Blecker U. Escherichia coli and the hemolytic-uremic syndrome. South Med J 1998;91(9):798–804.

    Article  CAS  PubMed  Google Scholar 

  13. Statistics Canada. Profile series. Profile of age and sex for Canada, provinces, territories, census divisions and census subdivisions: 2001 Census. Ottawa, ON: Statistics Canada, 2002.

    Google Scholar 

  14. Decludt B, Bouvet P, Marian-Kurkdjian P, Grimont F, Grimont PAD, Hubert B, Loirat C. Haemolytic uraemic syndrome and shiga toxin-producing Escherichia coli infection in children in France. Epidemiol Infect 2000;124:215–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kathleen Laberge DVM, MSc.

Additional information

Acknowledgements: British Columbia Ministry of Health, Canadian Field Epidemiology Program, British Columbia Health Authorities staff, British Columbia Centre for Disease Control Laboratory Services.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laberge, K., Galanis, E. Evaluation of the Surveillance of Hemolytic Uremic Syndrome in British Columbia. Can J Public Health 99, 286–289 (2008). https://doi.org/10.1007/BF03403756

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03403756

Mots clés

Key words

Navigation